This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.

开始日期2025-05-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT06319196

/ Recruiting临床2期IIT

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High Risk Melanoma

Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable circulating tumor deoxyribonucleic acid (ctDNA) following definitive surgery for high risk melanoma. Patients will be allocated to either Arm A or Arm B via the process of randomization. The randomization process will be stratified according to stage (Stage 2A/2B/3A/3B/3C/3D or 4), to ensure absolute balance between stage groups. The investigators are choosing only 1 stratification factor, disease stage, as the investigators consider stage being the most significant prognosticating variable. Each stage represents a biologically distinct entity with varying recurrence rate outcomes. Block randomization will be performed to ensure equal sample sizes in the combination and monotherapy arms. At least 54 patients will be included in the randomized part of the study. The investigators are expecting approximately 20% of the patients to have detectable ctDNA after definite surgery. Therefore, approximately 270 patients are expected to be enrolled and tested for ctDNA in the entire study.

开始日期2025-03-31

申办/合作机构

University Health Network

NCT06697197

/ Recruiting临床1/2期

A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

开始日期2025-03-03

申办/合作机构

Bristol Myers Squibb Co.

100 项与纳武利尤单抗/瑞拉利单抗相关的临床结果

登录后查看更多信息

100 项与纳武利尤单抗/瑞拉利单抗相关的转化医学

登录后查看更多信息

100 项与纳武利尤单抗/瑞拉利单抗相关的专利（医药）

登录后查看更多信息

项与纳武利尤单抗/瑞拉利单抗相关的文献（医药）

2023-12-31·mAbs

Antibodies to watch in 2023

Article

作者: Crescioli, Silvia ; Kaplon, Hélène ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Chenoweth, Alicia

In this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecast events that might occur in 2023. As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevimab (Beyfortus), mirvetuximab soravtansine (ELAHERE™), and teplizumab (TZIELD)), including 4 bispecific antibodies and 1 ADC. Based on FDA action dates, several additional product candidates could be approved by the end of 2022. An additional seven were first approved in China or Japan in 2022, including two bispecific antibodies (cadonilimab and ozoralizumab). Globally, at least 24 investigational antibody therapeutics are undergoing review by regulatory agencies as of mid-November 2022. Our data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline grew by ~20% in the past year to include nearly 140 investigational antibody therapeutics that were designed using a wide variety of formats and engineering techniques. Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).

2023-06-01·ANNALS OF PHARMACOTHERAPY

Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma

Review

作者: Reeves, David J. ; Phillips, Allison L.

Objective::

The aim of this article is to assess available data regarding use of nivolumab/relatlimab for adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

Data Sources::

A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications.

Study Selection and Data Extraction::

Relevant clinical trials written in English language were analyzed.

Data Synthesis::

Nivolumab/relatlimab was approved by the Food and Drug Administration following results of a phase 1/2 trial and phase 2/3 RELATIVITY-047 trial. Nivolumab/relatlimab demonstrated a median progression free survival (PFS) of 10.1 months in the first-line setting without new safety signals. The PFS benefits appear greatest in those with programmed cell death-ligand 1 (PD-L1) <1% and lymphocyte activation gene-3 (LAG-3) ≥1%. Adverse effects commonly experienced were immune related in nature and require early identification and prompt management. Grade 3 or 4 adverse effects occurred in 18.9% of patients.

Relevance to Patient Care and Clinical Practice::

For patients 12 years of age and older with unresectable or metastatic melanoma, nivolumab/relatlimab offers a new first-line treatment option. Evaluation of PD-L1 expression along with concomitant use of medications with potential interactions should be evaluated when deciding if nivolumab/relatlimab is the most appropriate treatment option.

Conclusions::

Nivolumab/relatlimab adds an additional first-line treatment option demonstrating promising improved PFS for patients with unresectable or metastatic melanoma, particularly those with PD-L1 <1% and/or LAG 3 ≥1%. Additional uses of nivolumab/relatlimab may be on the horizon as further clinical trials are ongoing.

2022-06-01·Drugs

Nivolumab Plus Relatlimab: First Approval

Review

作者: Paik, Julia

Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag^™) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers. Both drugs are immunoglobulin G4 (IgG4) monoclonal antibodies developed to target immune checkpoints, with nivolumab targeting the programmed cell death protein 1 (PD-1) receptor and relatlimab being a newly developed, first-in-class drug targeting the lymphocyte-activation gene 3 (LAG-3) protein. In March 2022, nivolumab plus relatlimab received its first approval in the USA for the treatment of unresectable or metastatic melanoma in adult patients and paediatric patients aged ≥ 12 years who weigh ≥ 40 kg. This article summarizes the milestones in the development of this combination therapy leading to this first approval for unresectable or metastatic melanoma.

185

项与纳武利尤单抗/瑞拉利单抗相关的新闻（医药）

2025-03-09

·蒲公英Ouryao

谁家抗癌药最畅销？2024全球肿瘤药企TOP3出炉

随着科技的飞速发展和人类对癌症认知的不断深入，2024年的全球制药肿瘤行业迎来了新一轮的洗牌。今天，就让我们一起揭晓2024年全球制药肿瘤行业排名TOP10，看看TOP3的企业是哪些？哪些产品又占据了前三甲？在肿瘤产品市场前三甲的激烈排位争夺战中，默沙东凭借史上最畅销的肿瘤药物K药强势卫冕。与此同时，BMS与罗氏之间的竞争态势愈发白热化。靠着实体瘤和血液瘤两大板块的多元扩张，两者的肿瘤业务收入都增长到了270亿美元量级，在肿瘤市场中形成了强有力的竞争格局，也为整个行业的发展注入了新的活力与变数。图 2024年全球制药巨头肿瘤业务排名TOP10 （来源：医药魔方） PART.01 2024年全球制药肿瘤业务TOP3企业 NO.3 罗氏凭借着实体瘤和血液瘤板块的双轮驱动增长，罗氏作为肿瘤霸主的辉煌再度闪耀，2024年其肿瘤业务收入达237.44亿瑞士法郎（约270.40亿美元），与BMS的肿瘤业绩已相差无几。 Tecentriq（阿替利珠单抗）和Perjeta（帕妥珠单抗）依然是罗氏实体瘤领域的两大拳头产品。在一众实体瘤产品中，治疗乳腺癌的HER2单抗复方制剂Phesgo（帕妥珠单抗曲妥珠单抗皮下注射制剂）的增长表现较为亮眼，同比增长62%至17.40亿瑞士法郎（约19.82亿美元）。此外，PI3Kα抑制剂Itovebi的获批也为罗氏的乳腺癌产品线注入了新的活力。在乳腺癌领域持续领跑的罗氏正通过外部创新巩固其优势。2024年9月，罗氏旗下基因泰克将以8.5亿美元的首付款收购锐格医药的下一代CDK抑制剂，这与罗氏现有的HER2、PI3K等靶向药物形成了更全面的产品矩阵。血液瘤领域，革新弥漫性大B细胞淋巴瘤（DLBCL）一线治疗的CD79b ADC药物Polivy展现不错的产品力，以11.21亿瑞士法郎（约12.77亿美元）的销售额跻身重磅炸弹行列。两款主打适应症差异化的CD3/CD20双抗Columvi和Lunsumio还在起量阶段。通用型CAR-T疗法的开发有望进一步强化罗氏在血液瘤领域的实力。2024年11月，罗氏以15亿美元收购了Poseida Therapeutics。罗氏认为，基于后者的技术平台打造的通用型CAR-T疗法有潜力成为各治疗领域的同类最佳产品。 NO.2 BMS BMS的肿瘤业务十分庞大，实体瘤与血液瘤两大板块齐头并进。Opdivo（纳武利尤单抗）仍是BMS在实体瘤领域的扛大旗者，2024年销售收入93.04亿美元，同比增长3%。 BMS始终跑在免疫联合赛道的前沿。Yervoy（伊匹木单抗）销售额稳健增长，O药+Y药的免疫双子星组合还于2024年在中国迎来了新适应症的全球首批，一线治疗MSI-H/dMMR结直肠癌患者。PD-1+LAG-3组合疗法Opdualag（纳武利尤单抗+瑞拉利单抗）离重磅炸弹只有一步之遥。新一代ROS1/NTRK抑制剂Augtyro（瑞普替尼）和全球第2款KRAS G12C抑制剂Krazati（阿达格拉西）初露头角，2024年的全球销售额分别为0.38亿美元和1.26亿美元。在后期实体瘤管线的储备中，抗岩藻糖GM1神经节苷脂（Fucosyl-GM1）单抗atigotatug（BMS-986012）承载了BMS进击小细胞肺癌的雄心，其与O药一线联合治疗广泛期小细胞肺癌的III期研究已推进至III期阶段。血液瘤领域，CD19 CAR-T疗法Breyanzi因产能扩大释放了销售潜力，翻倍增长至7.47亿美元。BCMA CAR-T疗法Abecma销售有所下滑，为4.06亿美元。全球首个红细胞成熟剂Reblozyl（罗特西普）全年销售额达17.73亿美元，高增长主要由一线骨髓增生异常综合征导致的贫血患者的需求驱动。Revlimid（来那度胺）和Pomalyst/Imnovid（泊马度胺）两代度胺类产品合计贡献93.18亿美元。未来BMS在血液瘤领域将重点攻坚多发性骨髓瘤，其精准布局的GPRC5D CAR-T疗法arlo-cel、两款分子胶iberdomide和mezigdomide均已推进至III期阶段。 NO.1 默沙东全球肿瘤免疫标杆产品Keytruda（帕博利珠单抗）再度展现“药王”的实力，2024年以18%的增长速度创收294.82亿美元，不仅贡献了默沙东全年总营收46%的份额，更助力其坐稳了肿瘤领域NO.1的位置。默沙东从晚期适应症的覆盖到早中期的前移探索，从单药到联合，以及皮下制剂的开发。就以早期肿瘤的治疗来说，K药是唯一在4项研究中显示出显著OS获益的肿瘤免疫疗法，并获得了9项适应症批准。其他肿瘤产品也均处于增长之中。全球首创HIF-2α抑制剂Welireg于2021年上市，如今似乎进入了快速放量阶段，2024年取得5.09亿美元的销售额，同比增长133%。Lynparza（奥拉帕利）和Lenvima（仑伐替尼）则分别带来了13.11亿美元和10.10亿美元的收入分成。基于现有的业务布局，默沙东认为在肿瘤领域还有250亿美元的潜在市场机会。要将这250亿美元的潜在价值转化为实际收益，ADC药物将打出关键组合拳。通过与第一三共和科伦博泰等ADC龙头企业的合作，默沙东快速收获了一系列管线，覆盖HER3、B7-H3、CDH6和TROP2诸多潜力靶点。其中，HER3-DXd已申报上市。 PART.02 2024年肿瘤产品销售额TOP3 No.3 / Opdivo（纳武利尤单抗） 2024年，BMS的Opdivo（纳武利尤单抗）销售收入93.04亿美元，加上来自小野制药的8.40亿美元，总销售额达到101.44亿美元。纳武利尤单抗目前已在包括美国、欧盟、日本和中国在内的超过65个国家和地区获得批准上市，涵盖12个瘤种，包括肺癌、头颈癌、胃癌、食管癌、肝癌、肾癌、结直肠癌、尿路上皮癌、黑色素瘤、霍奇金淋巴瘤、胸膜肿瘤、不明原发部位肿瘤。纳武利尤单抗的专利将于2028年到期，BMS正通过推出皮下制剂等方式延长产品生命周期。2024年12月28日，FDA批准了Opdivo皮下注射剂Opdivo Qvantig（nivolumab加透明质酸酶）上市，用于所有已批准的Opdivo适应症，意味着Opdivo成为全球首款获批上市的PD-1皮下制剂。 No.2 / Darzalex（达雷妥尤单抗）强生的达雷妥尤单抗（Darzalex）作为治疗多发性骨髓瘤的靶向CD38单抗，2024年全球销售额达116.70亿美元，同比增长19.8%，首次突破百亿美元大关。达雷妥尤单抗的组合物专利将于2026年3月到期，国内药企中，正大天晴、复宏汉霖、九源基因都有在研的生物类似药。 No.1 / Keytruda（帕博利珠单抗） 2023年的药王Keytruda（帕博利珠单抗）营收高达294.82亿美元，同比增长18%，其销售额约占默沙东全年总营收的46%，成功卫冕2024年的全球药王。2024其增长主要源于全球范围内对转移适应症的需求持续强劲，包括新增膀胱癌、子宫内膜癌适应症以及包括三阴性乳腺癌和非小细胞肺癌等在内的早期适应症。不过，K药的部分关键专利将在2028年到期，生物类似药的涌入和国产PD-1的“出海”都将蚕食其市场份额。 2024年全球制药肿瘤行业排名TOP10的出炉，不仅展现了各家药企在肿瘤领域的实力，也为未来肿瘤治疗的发展指明了方向。免疫治疗发展迅速，联合治疗方式因其显著疗效而逐渐成为研究热点。此外，部分药企借助AI技术辅助药物研发，加速了药物研发的速度，也提升了治疗方案的精准性。 END 参考来源：1、2024年全球制药巨头肿瘤业务排名TOP10 https://mp.weixin.qq.com/s/MKFoIGw04PieE5A8Jzn2bQ 2、谁是肿瘤药之王?2024年全球肿瘤药品TOP3https://mp.weixin.qq.com/s/BTaHwf13fUWJBhEaBedbSw 声明：本文仅代表作者个人观点，不代表任何组织及本公众号立场，如有不当之处，敬请指正。如需转载，请注明作者及来源：蒲公英Biopharma。

免疫疗法细胞疗法抗体药物偶联物并购

2025-03-06

·PRNewswire

TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but TEPMETKO's once-daily dosing and efficacy profile offer differentiation. LAS VEGAS, March 6, 2025 /PRNewswire/ -- DelveInsight's " TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase inhibitor indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of TEPMETKO. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. EMD Serono's TEPMETKO (tepotinib) Overview TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as hydrochloride monohydrate), administered orally. Patients should be cautioned about the heightened risk of severe or fatal interstitial lung disease/pneumonitis, liver toxicity, and potential embryo-fetal toxicity, necessitating effective contraception during and shortly after treatment. Tepotinib specifically targets MET, including variants with exon 14 skipping mutations. It blocks HGF-dependent and independent MET phosphorylation, disrupting MET-driven signaling pathways. Additionally, at clinically relevant concentrations, Tepotinib inhibits melatonin 2 and imidazoline 1 receptors. In vitro studies show that it suppresses tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent cancer cells. In mouse models with MET-driven tumors, including those with MET exon 14 skipping alterations, Tepotinib reduced tumor growth, sustained MET phosphorylation inhibition, and, in one case, decreased metastasis formation. The recommended dose of TEPMETKO is 450 mg taken orally once daily until disease progression or intolerable toxicity occurs. Patients should take it at the same time each day, swallowing tablets whole without chewing, crushing, or splitting them. If a dose is missed and less than eight hours remain until the next scheduled dose, patients should skip it. In cases of vomiting after taking TEPMETKO, the next dose should be taken at the usual time. Learn more about TEPMETKO projected market size for NSCLC @ TEPMETKO Market Potential Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 81% of all diagnosed cases. Early detection greatly improves outcomes, but diagnosing NSCLC and other lung cancers is challenging because their symptoms are often mistaken for common illnesses or the long-term effects of smoking. Consequently, 80% of NSCLC cases are already at advanced stages by the time they are identified, making treatment more difficult. Around 80% of EGFR mutations in NSCLC involve either exon 19 deletions or the exon 21 L858R substitution, both of which are classified as sensitizing mutations. Until the last decade, chemotherapy was the primary treatment for advanced and metastatic lung cancer. However, this changed in 2015 with the approval of the first immune checkpoint inhibitor (ICI), KEYTRUDA (pembrolizumab), as a second-line therapy for advanced cases. This was followed by TECENTRIQ (atezolizumab) in 2016. Both therapies were later approved for first-line treatment, broadening their use to a larger patient population. In 2020, the combination of OPDIVO (nivolumab) and ipilimumab also received approval as a first-line treatment for metastatic NSCLC. According to DelveInsight, the NSCLC market size across the 7MM is projected to grow from USD 30 billion in 2024, with a substantial CAGR through 2034. This growth is largely driven by the introduction of emerging therapies during the forecast period (2025–2034). Discover more about the NSCLC market in detail @ Non-small Cell Lung Cancer Market Report Emerging Competitors of TEPMETKO The NSCLC pipeline is very robust with the promising therapies such as Telisotuzumab vedotin (AbbVie), Patritumab deruxtecan (Daiichi Sankyo/AstraZeneca), Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca), Eftilagimod alpha (Immutep), BNT311/GEN1046 (acasunlimab) (Genmab), V940 (mRNA-4157) + Pembrolizumab (Moderna Therapeutics/Merck), Plinabulin + Docetaxel (BeyondSpring), Olomorasib (LY3537982) (Eli Lilly and Company), Zipalertinib (Cullinan Oncology/Taiho Pharma), Ceralasertib (AZD6738) (AstraZeneca), TEDOPI (EP-2101; IDM 2101; OSE-2101) (OSE Immuno-therapeutics), Sigvotatug vedotin (PF08046047) (Pfizer), ANKTIVA (N-803) (ImmunityBio), Aumolertinib/Almonertinib/HS-10206 (Jiangsu Hansoh Pharmaceutical), Niraparib (GSK), Savolitinib (AstraZeneca/Hutchison MediPharma), TRODELVY (Gilead Sciences), Pyrotinib (Jiangsu HengRui Medicine), Ociperlimab (BGB-A1217) (BieGene), Volrustomig (AstraZeneca), Gotistobart (BNT316/ONC-392) (OncoC4/BioNTech), Ivonescimab (AK112/SMT112) (Akeso Biopharma/Summit Therapeutics), ZYNYZ (retifanlimab/INCMGA00012) (Incyte/Macrogenics), Divarasib (GDC-6036) (Roche/Genentech), Tiragolumab (RG6058) (Roche), Sacituzumab Tirumotecan (Merck and Kelun-Biotech), JEMPERLI (dostarlimab/TSR-042) (GSK and AnaptysBio), Zongertinib (BI-1810631) (Boehringer Ingelheim), BAY 2927088 (Bayer), Serplulimab (HLX10) (Shanghai Henlius Biotech), Rilvegostomig (AZD2936) (AstraZeneca), MK-1084 (Merck, Taiho Pharmaceutical, and Astex), Domvanalimab (Arcus Biosciences and Gilead Sciences), OPDUALAG (nivolumab and relatlimab) (Bristol-Myers Squibb), Belrestotug + JEMPERLI (iTeos Therapeutics and GSK), Firmonertinib (ArriVent BioPharma), Sunvozertinib (DZD9008) (Dizal Pharmaceutical), Cobolimab (GSK), Livmoniplimab (AbbVie), Fianlimab (REGN3767) (Regeneron Pharmaceuticals), BNT327/PM8002 (Biotheus/BioNTech), HS-20117 (Hansoh BioMedical), IO102-IO103 + Pembrolizumab (IO Biotech), Naptumomab estafenatox (NeoTX Therapeutics/Active Biotech), FF-10832 (FUJIFILM Corporation), BNT116 (BioNTechSE/Regeneron Pharmaceuticals), CAN-2409 (Candel Therapeutics), Mecbotamab Vedotin (BA3011/CAB-AXL-ADC) (BioAtla), Bemcentinib (BGB 324/BGB-3234/R-428) (BerGenBio/Rigel Pharmaceuticals), DOVBLERON (taletrectinib/AB-106/IBI-344) (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku), Lifileucel (Iovance Biotherapeutics), IBI363 (Innovent Biologics), Sotevtamab (AB-16B5) (Alethia Biotherapeutics), Avutometinib (VS6766) (Verastem Oncology), Vebreltinib (APL-101) (Apollomics), LP-300 (Lantern Pharma), JNJ-90301900 (Johnson & Johnson Innovative Medicine), AMG 193 (Amgen), Luveltamab tazevibulin (Sutro Biopharma), PRT3789 (Prelude Therapeutics), Disitamab vedotin (Seagen), PADCEV (enfortumab vedotin) (Astellas Pharma), RP1 (Replimune), TIVDAK (tisotumab vedotin) (Seagen), Zanidatamab (Jazz Pharmaceuticals), Utidelone injectable (UTD1) (Beijing Biostar Pharmaceuticals), REGN5093-M114 (Regeneron Pharmaceuticals), SLC-391 (SignalChem Lifesciences), fulzerasib (GenFleet), Davutamig (REGN5093) (Regeneron Pharmaceuticals), TAS3351 (Taiho Oncology), H002 (RedCloud Bio), JIN-A02 (J INTS BIO), FWD1509 (Forward Pharma), Sabestomig (AZD7789) (AstraZeneca), Sasanlimab (Pfizer), Selvigaltin (GB1211) (Galecto Biotech), Vepafestinib Helsinn (Healthcare/Taiho Pharmaceutical), EP0031 (A400/ KL590586) (Ellipses Pharma/Kelun-Biotech), Pamvatamig (MCLA-129) (Merus), Zidesamtinib (NVL-520) (Nuvalent), NVL-655 (Nuvalent), RMC-4630 (Revolution Medicines), REQORSA (quaratusugene ozeplasmid) (Genprex), PDC*lung01 (PDC*line Pharma), Evalstotug (BA3071) (BioAtla and BeiGene), PT-112 (Promontory Therapeutics), MRT-2359 (Monte Rosa Therapeutics), GAIA-102 (GAIA BioMedicine), Rigosertib (Traws Pharma), HMBD-001 (Hummingbird Bioscience), PLB1004 (Avistone Biotechnology), ANS03 (Avistone Biotechnology), MYTX-011 (Mythic Therapeutics), A166 (Sichuan Kelun-Biotech Bio-pharmaceutical), Atamparib (BN-2397) (Ribon Therapeutics), DELTACEL (KB-GDT-01) (Kiromic BioPharma), Carotuximab (ENV-105) (Kairos Pharma), YL202 (MediLink Therapeutics), and others. To know more about the number of competing drugs in development, visit @ TEPMETKO Market Positioning Compared to Other Drugs Key Milestones of TEPMETKO In February 2024, the FDA granted traditional approval to TEPMETKO for adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. In February 2022, the EC approved TEPMETKO as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to METex14 skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. In February 2021, Merck announced that the US FDA has approved TEPMETKO following priority review for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This indication was approved under accelerated approval based on ORR and DOR. In October 2020, TEPMETKO received ODD for treating NSCLC with MET genomic tumor aberrations In March 2020, EMD Serono (the biopharmaceutical business of Merck KGaA), announced that the MHLW approved TEPMETKO for the treatment of patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations. In September 2019, the US FDA granted BTD for tepotinib in patients with metastatic NSCLC harboring METex14 skipping alterations who progressed following platinum-based cancer therapy Discover how TEPMETKO is shaping the NSCLC treatment landscape @ TEPMETKO NSCLC TEPMETKO Market Dynamics TEPMETKO competes in a growing but highly specialized market where MET-targeted therapies are gaining traction due to their efficacy in addressing MET-altered tumors. The market for MET inhibitors is expanding as precision oncology advances and molecular diagnostics become more widely available, enabling better identification of patients who would benefit from targeted treatments like TEPMETKO. A key factor shaping TEPMETKO's market dynamics is competition. It directly competes with Novartis' TABRECTA (capmatinib), another MET inhibitor approved for the same indication. While TEPMETKO offers the advantage of once-daily dosing compared to TABRECTA's twice-daily regimen, both drugs have similar efficacy profiles, making physician and patient preference an important differentiator. Additionally, broader competition from next-generation MET inhibitors and combination therapies in clinical trials could impact TEPMETKO's long-term market position. Regulatory approvals and market access play a crucial role in TEPMETKO's adoption. The drug has been approved in multiple regions, including the U.S., Europe, and Japan, but reimbursement and pricing strategies vary by market. Payer policies, along with the cost-benefit analysis of MET inhibitors compared to other targeted therapies, influence prescription trends. Furthermore, real-world evidence and post-marketing studies will be critical in demonstrating TEPMETKO's sustained effectiveness and safety, which could support expanded indications and increased market penetration. Looking ahead, the MET inhibitor market is expected to grow with advances in biomarker-driven therapy, further refining patient selection. TEPMETKO's success will depend on continued clinical development, potential label expansions, and strategic partnerships to strengthen its competitive edge. As new entrants emerge, Merck KGaA's ability to differentiate TEPMETKO through combination strategies or enhanced formulations may determine its long-term sustainability in this evolving landscape. Dive deeper to get more insight into TEPMETKO's strengths & weaknesses relative to competitors @ TEPMETKO Market Drug Report Table of Contents Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality biologics, among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. C-MET Metastatic Non-small Cell Lung Cancer Market C-MET Metastatic Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key C-MET mNSCLC companies, including Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, among others. C-MET Non-small Cell Lung Cancer Pipeline C-MET Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key C-MET non-small cell lung cancer companies, including AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准免疫疗法优先审批

2025-02-21

·药闻康策

翻遍十家MNC财报，寻找2025年医药增长爆点

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策随着各大MNC陆续披露2024年业绩，全球新的药物格局已经逐渐清晰。全球销售额TOP 10的名单中，共有2款GLP-1药物、3款自免药物、2款抗肿瘤药物。默沙东的“王牌”Keytruda（K药）继续称雄，诺和诺德的Ozempic（司美格鲁肽）和赛诺菲/再生元的Dupixent分类二三位。整体来看，肿瘤药物的热度正在消退，GLP-1药物、自免药物已然成为全球药物新的发展方向。图：2025年全球药物TOP 10，来源：锦缎研究院当然，这只是当下全球药物的销售情况，仅代表已经发生的过去。对于投资者而言，更重要的是找到哪些尚未爆发的潜在机会，这也是本文研究的初衷。经过全面的系统复盘，我们努力形成了一份十大MNC未来的增长点清单。 01 默沙东：紧抱K药好消息是，默沙东的K药太强了！坏消息是，除了K药之外，默沙东几乎没有新的增长点。凭借K药的强势表现，默沙东在2024年取得641.68亿美元的营收，同比增长7%。但公司整体营收增速是要明显低于K药18%增速的，这意味着默沙东K药之外的产品表现不尽如人意。所有肿瘤产品中，唯有HIF - 2α抑制剂Welireg表现亮眼，实现同比增长133%，不过其营收规模仅为5.09亿美元，尚不能成为公司的核心增量。图：默沙东核心药物一览，来源：锦缎研究院一直以来，疫苗业务都是默沙东重要的第二增长点，但随着HPV疫苗在中国市场的饱和，进而造成默沙东整体疫苗业务失速，HPV疫苗Gardasil/Gardasil 9的全年营收为85.83亿美元，同比下降3%。默沙东虽然拥有K药这个大杀器，但后续管线潜力不足。目前公司唯一的战略就是竭力放大K药的营收，但这也加剧了K药遭遇专利悬崖后的风险。 02 礼来：GLP-1全面爆发 GLP-1药物的全面爆发，造就了礼来全球药王的地位。 2024年，礼来全球营收450.43亿美元，同比增长32%，主要受GLP-1药物爆发带动。礼来的两款GLP-1药物Mounjaro（替尔泊肽糖尿病版）和Zepbound（替尔泊肽减重版）合计贡献营收164.66亿美元，同比暴增208%。Zepbound上市的第一个完整年度就爆卖49.26亿美元，几乎复刻当初Mounjaro的奇迹。图：礼来核心药物一览，来源：锦缎研究院除GLP-1药物的爆发外，礼来的CDK4/6抑制剂Verzenio也取得惊喜。凭借2023年3月率先拿下早期乳腺癌适应症，Verzenio成功超越辉瑞的Ibrance，成为全球最成功的CDK4/6抑制剂。SGLT2抑制剂Jardiance也有不错的增长，但由于其合作方BI尚未公布财报，因此暂不列入讨论范畴。放眼未来，GLP-1药物将成为礼来持续增长的核心，同时礼来的阿尔兹海默症新药Donanemab在去年上市，或将进一步助推礼来业绩的爆发。基于此，礼来极有可能霸占“药王”宝座很长时间。 03 诺和诺德：做深GLP-1 不同于礼来突然爆发，诺和诺德则是持续深耕GLP-1药物的各种场景。在GLP-1药物的带动下，诺和诺德2024年营收约405亿美元，同比增长25%。具体来看，诺和诺德销售额前三的产品分别是Ozempic、Wegovy（司美格鲁肽减重版）、Rybelsus（司美格鲁肽口服版），仅司美格鲁肽一款产品就累计贡献近280亿美元的营收。图：诺和诺德核心药物一览，来源：锦缎研究院诺和诺德值得称道的地方，就在于能够持续挖掘用户的需求，在司美格鲁肽传统版本基础上，持续迭代出减重版与口服版，以拥抱更多的用户群去进行竞争。不过，除了司美格鲁肽这单一爆款外，诺和诺德其他产品的亮点并不多，这也是为何其股价不及礼来的地方。尽管诺和诺德短板明显，但其向来以实用主义著称，谁也不知道其未来会迭代出怎样具有想象力的产品。 04 强生：成熟稳健纵观所有MNC企业，强生绝对是最成熟稳健的一家。整个2024年，强生总营收达888亿美元，同比增长4.3%。其中创新药营收569.64亿美元，医疗器械营收318.57亿美元，营收增速均在4%以上。这里我们暂不考虑医疗器械，仅聚焦于强生创新药产品。虽然强生并没有K药和GLP-1那样吸睛的药物，但其却拥有两款年营收额突破100亿美元的产品。这也就意味着，强生并没有特别依赖于某一款产品，而是依靠丰富的产品矩阵创造营收，保证强生在Imbruvica、Stelara、Remicade、Simponi营收下滑的情况下仍能够继续增长。图：强生核心药物一览，来源：锦缎研究院纵观强生产品线，涵盖肿瘤、自免、抗病毒、CAR-T、CNS（中枢神经系统）等众多赛道。其中，治疗前列腺癌的Erleada、治疗抑郁症的SPRAVATO，以及治疗血液瘤的CARVYKTI有望担任营收增量角色，它们均在2024年取得喜人的数据。尤其是强生在收购了Intra-Cellular后，或将进一步增加对于CNS赛道的投入力度。收购而来的Caplyta，或将与SPRAVATO形成产品共振，构建属于强生自己的抗抑郁护城河。 05 阿斯利康：增长周期 “骗保窝案”让阿斯利康中国深陷“舆论中心”，但其全球业务却增长喜人。如果说强生的产品组合成熟稳健的话，那么阿斯利康的产品组合则彰显出朝气蓬勃。在2024年，阿斯利康共实现营收540.73亿美元，同比增长21%。与强生类似，阿斯利康的营收也并非由大单品贡献，而是凭借丰富的管线构建所实现。图：阿斯利康核心药物一览，来源：锦缎研究院具体来看，阿斯利康的所有管线中，虽没有营收突破百亿美元的“大爆款”，但却有多达7款核心产品的营收实现20%以上的同比增长，其中还没有包括EGFR抑制剂奥希替尼以及PD-L1抑制剂Imfinzi。尤其在癌症领域，阿斯利康拥有奥希替尼、Imfinzi、Enhertu、Calquence等多个重量级产品，核心竞争力极强。仅从业务层面而论，阿斯利康构建起的产品矩阵正处于上升周期，有望在未来数年持续增长，进而助推公司更上一层台阶。 06 辉瑞：并购带动增长新冠红利消退、核心药物失速、RSV疫苗未达预期，辉瑞似乎麻烦不断。不过，辉瑞交出的2024年答卷却并没有那么糟糕。整个2024年，辉瑞共实现营收636.27亿美元，同比增长7%，没有消息面那样悲观。辉瑞最大的惊喜在于，新冠特效药Paxlovid的反弹，在2023年其营收跌至12.79亿美元后，Paxlovid在去年迅速反弹至57.16亿美元，成为2024年最让人惊喜的营收增量。此外，罕见病氯苯唑酸类药物Vyndaqel销售额54.51亿美元，同比增长64%，也助推了辉瑞的增长。图：辉瑞核心药物一览，来源：锦缎研究院当然，辉瑞营收增长不错还有另外一重推力，那就是持续并购所带来的新增量。依靠新冠红利，辉瑞赚得盆满钵满，并拿出一部分利润去进行连续收购。偏头疼药物Vydura、Nectin-4 ADC药物Padcev、CD30 ADC药物Adcetris均是辉瑞通过收购Biohaven公司和Seagen得来，这也使得辉瑞营收重新活力。一直以来，我们都认为辉瑞是一个机会主义者，其正在利用新冠时积累的红利释放增长。 07 BMS：重新激活PD-1 在与K药的PD-1争夺战中，Opdivo（O药）败下阵来，但这并不耽误O药成为一款百亿美元级别的“爆款”。与默沙东类似，BMS的核心策略也是围绕O药这款“基石”产品做文章。整个2024年，BMS共实现营收483亿元，同比增长7.3%，这一成绩是明显强于去年的（2023年营收同比降低2.5%）。除传统业务的增长外，BMS的核心增长点主要在两方面，其一罕见药Reblozyl的持续爆发；其二O药矩阵的重新激活。图：BMS核心药物一览，来源：锦缎研究院 Reblozyl是一款治疗罕见血液病β地中海贫血的药物，并作为对红细胞生成刺激剂（ESA）如促红细胞生成素等常规治疗无应答的骨髓增生异常综合征（MDS）患者的二线治疗。2023年8月，Reblozyl获批用于MDS一线疗法，极大地提升了这款药物的产业价值，这也是为何其能够在2024年营收同比暴增近76%的原因。另一方面，BMS围绕O药进行了一系列联用，无论是Yervoy的增长，还是Opdualag（PD-1+LAG-3复方制剂）的爆发，本质都是BMS试图利用联用疗法重新激活O药增长。这也有望成为BMS未来的核心增长点。 08 诺华：拥抱未来小核酸药物、核药，这两大类新兴药物赛道中，诺华已经成为绝对的龙头公司。积极拥抱未来的同时，诺华现阶段的核心药物增长势头同样迅猛。在2024年诺华实现营收503.17亿美元，同比增长12%。整个产品矩阵中，诺华共有4款产品营收增速突破40%，多达7款产品营收增速突破20%。图：诺华核心药物一览，来源：锦缎研究院营收增速突破40%的4款产品中，Kesimpta在多发性硬化症药物取得超预期表现，CDK4/6抑制剂Kisqali刚在欧洲获批早期乳腺癌，Pluvicto是最炙手可热的核药产品，Leqvio则是新一代降血脂的小核酸药物。这四款药物均有望在未来持续延续增长。从我们的视角观测，诺华的研发策略始终不拘一格，也是所有MNC中拥抱未来做得最好的。 09 不可或缺的替代疗法修美乐跌落神坛后，曾有不少投资者认为艾伯维将会一蹶不振，但谁也没有想到仅用两年时间就恢复元气。 2024年度，艾伯维共实现营收563.34亿美元，同比增长3.7%。从表面上看，艾伯维3.7%的增速似乎并不高，但若考虑修美乐过去两年蒸发的122亿美元营收，投资者就能知道艾伯维这个业绩得来的不容易，而且艾伯维还是在自免领域重新恢复的增长。图：艾伯维核心药物一览，来源：锦缎研究院进一步聚焦，艾伯维的核心增长来自两款自免产品，IL-23单抗Skyrizi和JAK1抑制剂Rinvoq的爆发式增长，两者均在2024年实现50%的同比增速。能够如此短时间就让自免赛道重回增长，可见当初修美乐的成功并非偶然，艾伯维依然在自免领域建立极为深厚的商业化渠道和产业护城河。除两款自免新锐的爆发外，艾伯维的抗抑郁症药物Vraylar也实现18.4%的同比增长，目前其正是全球最热门的抗抑郁药物。BCL-2抑制剂Venclexta增速稳定，销售额达到25.83亿美元，同比增长12.9%。放眼未来，自免与血液瘤，仍是艾伯维的核心阵地，目前艾伯维也正在通过持续BD去进一步深化在这两个领域的布局。此外，87亿美元收购Cerevel后，CNS也将成为艾伯维未来布局的重点。“自免+血液瘤+CNS”这将是艾伯维未来的方向。 10 罗氏：重塑增长凭借“单抗三驾马车”，罗氏成为当年最炙手可热的创新药公司，但当生物类似药逐渐多起来后，罗氏的关注度也正在下降。目前，罗氏的核心战略就是重塑增长。在2024年中，罗氏共实现营收约688.92亿美元，其中制药营收业务约525.8亿美元，同比增长8%。罗氏的四大核心产品实则都遭遇营收放缓的问题：CD20单抗Ocrevus营收同比增速降至5.7%；FIXa/FX双抗Hemlibra营收增速降至8.6%；PD-L1单抗Tecentriq营收同比下降3.3%；HER2单抗Perjeta营收同比下降4%。图：罗氏核心药物一览，来源：锦缎研究院但幸运的是，核心产品增长放缓的同时，罗氏已经找到了破局方向。Vabysmo是全球首款眼科双抗药物，在去年实现64%的营收增长，已经成为40亿美元级别的产品；Phesgo则是一款Perjeta+Herceptin的复方药物，重新激活了罗氏在HER2单抗领域的增长。业绩放缓的同时，罗氏的新产品也在放量，重塑增长将是罗氏未来一段时间的核心任务。 (来源：医曜作者：林药师）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

财报疫苗

100 项与纳武利尤单抗/瑞拉利单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性黑色素瘤	欧盟	Bristol-Myers Squibb Pharma EEIG	2022-09-15
转移性黑色素瘤	冰岛	Bristol-Myers Squibb Pharma EEIG	2022-09-15
转移性黑色素瘤	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2022-09-15
转移性黑色素瘤	挪威	Bristol-Myers Squibb Pharma EEIG	2022-09-15
不可切除的黑色素瘤	欧盟	Bristol-Myers Squibb Pharma EEIG	2022-09-15
不可切除的黑色素瘤	冰岛	Bristol-Myers Squibb Pharma EEIG	2022-09-15
不可切除的黑色素瘤	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2022-09-15
不可切除的黑色素瘤	挪威	Bristol-Myers Squibb Pharma EEIG	2022-09-15
黑色素瘤	美国	Bristol Myers Squibb Co.	2022-03-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
PD-L1阳性非鳞状非小细胞肺癌	临床3期	美国	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	日本	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	阿根廷	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	澳大利亚	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	奥地利	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	比利时	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	巴西	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	智利	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	丹麦	Bristol Myers Squibb Co.	2024-10-07
PD-L1阳性非鳞状非小细胞肺癌	临床3期	法国	Bristol Myers Squibb Co.	2024-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05002569 (RELATIVITY-098, Company_Website) 人工标引	临床3期	黑色素瘤辅助	-	Opdualag	衊艱簾鬱膚憲願鏇遞廠(選繭獵餘鑰齋製廠淵糧) = did not meet its primary endpoint. 選鏇鏇製積糧鏇顧構獵 (艱遞鹽遞襯鬱鏇膚獵鹽 ) 未达到	不佳	2025-02-13
				Opdivo
ESMO2024 人工标引	N/A	黑色素瘤二线 \| 一线 \| 新辅助	205	Nivolumab/Relatlimab	鬱積憲衊齋遞窪簾夢襯(襯顧遞襯顧鬱願鹹糧艱) = 醖膚積壓範獵襯壓範築壓積蓋夢構範鬱衊繭夢 (網製鏇蓋壓構積繭網糧 ) 更多	积极	2024-09-14
				Nivolumab/Relatlimab (subsequent line(C2))	鬱積憲衊齋遞窪簾夢襯(襯顧遞襯顧鬱願鹹糧艱) = 艱願願窪壓壓繭獵鹽淵壓積蓋夢構範鬱衊繭夢 (網製鏇蓋壓構積繭網糧 ) 更多
NEWS 人工标引	临床2/3期	黑色素瘤	714	Opdualag	範窪糧積鹽艱鏇範鹹醖(淵觸齋衊糧製範積衊獵) = 窪淵繭範簾襯鑰廠獵觸蓋遞選範選願範壓襯構 (窪範遞艱範蓋鏇範餘壓 )	积极	2024-01-03
				nivolumab	範窪糧積鹽艱鏇範鹹醖(淵觸齋衊糧製範積衊獵) = 醖製餘積襯壓鏇鏇窪選蓋遞選範選願範壓襯構 (窪範遞艱範蓋鏇範餘壓 )
NCT03662659 (RELATIVITY-060, CTgov)	临床2期	胃食管交界处癌 \| 胃食管交界处腺癌	274	BMS986213 (BMS986213 + Chemotherapy)	網選艱餘顧醖積積範獵(鏇鏇積衊遞築積襯鹹餘) = 膚蓋襯廠製鏇艱夢築膚壓餘憲蓋獵齋憲鑰壓窪 (鑰獵遞夢觸構積遞鏇網, 壓膚襯廠鬱鹹願範壓壓 ~ 築選膚願鑰鑰製積齋獵) 更多	-	2022-05-09
				Nivolumab (Nivolumab + Chemotherapy)	網選艱餘顧醖積積範獵(鏇鏇積衊遞築積襯鹹餘) = 鬱襯鹹鏇糧構壓積製淵壓餘憲蓋獵齋憲鑰壓窪 (鑰獵遞夢觸構積遞鏇網, 糧窪壓鏇觸餘築積網構 ~ 鹹構簾簾獵鹽鏇醖蓋獵) 更多